MitoRx Therapeutics announces appointments

UK biotech MitoRx Therapeutics has announced appointments, with Christine Charman named as chief development officer, David Richardson as finance director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd Schwahn.

MitoRx) is a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases,

Christine Charman comes with close to 26 years’ experience in accelerating transformational therapies as senior global program lead for Takeda’s (TYO: 4502) rare diseases, respiratory and immunology and neuroscience therapy areas. She also worked as consultant CDO at Izana Bioscience and development consultant for a range of biotechs and newcos and program lead supporting UK Vaccine and Antiviral Task Forces, with further development experience at Novartis (NOVN: VX) from pre-clinical research leadership to senior global program Director, including the planning, clinical execution and launch of two products.